TriSalus Life Sciences, Inc. (TLSI)
- Previous Close
5.11 - Open
5.21 - Bid --
- Ask --
- Day's Range
5.14 - 5.51 - 52 Week Range
3.50 - 10.17 - Volume
34,587 - Avg. Volume
49,182 - Market Cap (intraday)
166.203M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.31 - Earnings Date Aug 12, 2025 - Aug 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.31
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
trisaluslifesci.comRecent News: TLSI
View MorePerformance Overview: TLSI
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLSI
View MoreValuation Measures
Market Cap
166.20M
Enterprise Value
181.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.42
Price/Book (mrq)
--
Enterprise Value/Revenue
6.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-84.67%
Return on Assets (ttm)
-85.52%
Return on Equity (ttm)
--
Revenue (ttm)
32.14M
Net Income Avi to Common (ttm)
-30.31M
Diluted EPS (ttm)
-1.31
Balance Sheet and Cash Flow
Total Cash (mrq)
13M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--